Roivant Sciences Ltd.
ROIV
$27.85
-$0.25-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -56.36% | -45.13% | -35.86% | -11.19% | -40.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.36% | -45.13% | -35.86% | -11.19% | -40.27% |
| Cost of Revenue | 23.98% | 29.03% | 31.59% | 26.39% | 55.51% |
| Gross Profit | -29.13% | -35.43% | -37.64% | -29.48% | -57.61% |
| SG&A Expenses | 26.70% | 26.09% | 79.08% | 70.63% | 85.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.36% | 27.52% | 53.67% | 47.12% | 18.40% |
| Operating Income | -27.86% | -30.45% | -57.79% | -49.57% | -22.07% |
| Income Before Tax | -59.12% | -118.01% | -119.43% | -114.92% | -112.41% |
| Income Tax Expenses | 1,318.16% | -13.69% | 28.53% | 124.03% | -125.37% |
| Earnings from Continuing Operations | -75.77% | -118.90% | -120.42% | -116.05% | -112.33% |
| Earnings from Discontinued Operations | -100.00% | 426.88% | 297.95% | 218.37% | 225.43% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 15.60% | 40.60% | 65.28% | 56.94% | 97.17% |
| Net Income | -593.91% | -107.77% | -110.36% | -103.95% | -102.61% |
| EBIT | -27.86% | -30.45% | -57.79% | -49.57% | -22.07% |
| EBITDA | -29.32% | -32.04% | -61.03% | -53.22% | -22.64% |
| EPS Basic | -751.06% | -109.22% | -111.82% | -104.46% | -102.48% |
| Normalized Basic EPS | -92.58% | -72.14% | -82.61% | -29.31% | -8.88% |
| EPS Diluted | -744.25% | -109.92% | -112.63% | -104.84% | -102.68% |
| Normalized Diluted EPS | -94.52% | -76.15% | -87.26% | -29.81% | -9.20% |
| Average Basic Shares Outstanding | -7.72% | -9.22% | -8.48% | -7.40% | -1.51% |
| Average Diluted Shares Outstanding | -9.11% | -11.79% | -11.05% | -7.23% | -1.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |